Document Preview Unavailable
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors
You might have access to this document
-
Try and log in through your institution to see if they have access to the full text.
Log in through your library